causal

Early Development Work Carries Little Profit Upfront

NADS partners with drug developers early in development, customizing oligonucleotides while earning little money, with the payback arriving if the drug reaches commercialization and volume ramps.

causalpending

Speaker

Marc

Evidence Quote

“But the payback is if they make it to commercialization and some of them are now moving to commercialization, that the volume really ramps.”

Source

Agilent: Back To The Lab— Business Breakdowns
Created: 11/12/2026, 11:55:35 AM

Your notes

Loading notes...